AGIO
Agios Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.70
P/S
37.74
EV/EBITDA
-4.54
DCF Value
$-22.71
FCF Yield
-18.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.3%
Operating Margin
-873.9%
Net Margin
-764.0%
ROE
-31.1%
ROA
-31.8%
ROIC
-38.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $20.0M | $-108.0M | $-1.85 |
| FY 2025 | $54.0M | $-412.8M | $-7.12 |
| Q3 2025 | $12.9M | $-103.4M | $-1.78 |
| Q2 2025 | $12.5M | $-112.0M | $-1.93 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.79
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.